The effects of cilazapril alone and in combination with frusemide in healthy subjects.
1. In a fourway double-blind placebo controlled study, the effects of cilazapril, a new angiotensin converting enzyme inhibitor, on renal function and the responses to intravenous frusemide were studied in a group of twelve salt depleted male volunteers. 2. Cilazapril produced an increase in effective renal plasma flow and urinary output of prostaglandin E2 metabolite (PGE2-M) but no effect on sodium, potassium or water excretion. 3. Pretreatment with cilazapril antagonised the effects of frusemide on glomerular filtration, PGE2-M and sodium excretion.
Johnston
G D
GD
Department of Therapeutics and Pharmacology, Queen's University, Belfast.
Passmore
A P
AP
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D017315:Cilazapril; D015232:Dinoprostone / Q000652:urine; D004311:Double-Blind Method; D005665:Furosemide / Q000008:administration & dosage / Q000494:pharmacology*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000187:drug effects*; D008297:Male; D011724:Pyridazines / Q000008:administration & dosage / Q000494:pharmacology*; D012083:Renin / Q000097:blood
D000806:Angiotensin-Converting Enzyme Inhibitors; D011724:Pyridazines; D017315:Cilazapril; D005665:Furosemide; D012083:Renin; D015232:Dinoprostone